Showa Denko Kabushiki Kaisha

Showa Denko K.k.

Hitachi Global Life Solutions, Inc.

Eiji Ogata

Shinobu Ito

Masahiro Suzuki

Tsutomu Nozawa

Yohei Kurata

Keisuke Mano

Toshi Tsuzuki

Naoaki Misu

Yutaka Oonishi

Takami Ooe

Hisae Shibuya

Tadashi Yoneda

Hiroshi Kusumoto

Keiko Oka

Kuniaki Shimbo

Kazuhiro Tsuchihashi

Yoko Kokugan

Masahiro Yamada

Eiko Kato

Norikazu Sasaki

Hiroshi Ikeno

Nobuhiko Miwa

Noriyuki Tokura

Jiro Takata

A refrigerant quantity diagnosis device includes: an evaluation value calculation part that calculates a refrigerant quantity index evaluation value including a ratio of a measured refrigerant quantity index value to a reference refrigerant quantity index value in each of a normal period and a determination period; and a refrigerant quantity diagnosis part that diagnoses a refrigerant quantity based on the refrigerant quantity index evaluation value. The evaluation value calculation part calculates a first refrigerant quantity index evaluation value in the normal period and a second refrigerant quantity index evaluation value in the determination period, based on respective reference refrigerant quantity index values having respective values associated with an operating condition of interest, and respective measured refrigerant quantity index values. The refrigerant quantity diagnosis part compares information on the first refrigerant quantity index evaluation value with that on the second one and thereby diagnoses the refrigerant quantity.

Refrigerant quantity diagnosis device, refrigerant system, and refrigerant quantity diagnosis method

An agent for skin external use of the invention contains a salt of higher fatty acid ester of ascorbic acid-2-phosphoric acid ester and a polyhydric alcohol. According to the present invention, occurrence of turbidity or precipitation with time can be prevented to enhance stability even when the agent for skin external use is prepared using a specific salt of higher fatty acid ester of ascorbic acid-2-phosphoric acid ester. Therefore, the present invention is useful for all agents for skin external use, particularly cosmetics.

Agent for skin external use containing salt of ascorbic acid derivative, method for stabilizing the agent for skin external use, and stabilizer

An object of the present invention is to provide a composition for enhancing the immunological effects of a vaccine for viruses, bacteria and/or infectious disease pathogens, containing a stable activity-type provitamin; a method for enhancing the immunological effects of a vaccine for viruses, bacteria and/or infectious disease pathogens by administering the composition; and a method of employing the composition. A composition for enhancing the immunological effects of a vaccine for viruses, bacteria and/or infectious disease pathogens, contains L-ascorbic acid-2-phosphate and/or &agr;-tocopheryl phosphate as a stable activity antioxidant provitamin.

Composition for enhancing immunological effects

Agent for preventing and treating skin diseases

L-Ascorbic acid 2-phosphate zinc salt and a salt hydrate thereof having excellent solubility and exhibiting good stability even under weakly acidic conditions. Also disclosed is a process of manufacturing L-ascorbic acid 2-phosphate zinc salt by displacing a cation of a salt of an L-ascorbic acid 2-phosphate other than a zinc salt with a zinc cation. Further disclosed is a composition containing L-ascorbic acid 2-phosphate zinc salt or a salt hydrate thereof as an active ingredient.

L-ascorbic acid 2-phosphate zinc salt and process for manufacturing the same

A preparation for administration to animals, comprising a sparingly soluble L-ascorbic acid-2-phosphoric ester salt having a solubility in water of 10 wt % or less, the solubility being a value obtained by placing 100 g of purified water in a 200 ml-volume beaker, stirring the water while keeping the temperature at 20&deg; C., adding 0.1 g of the L-ascorbic acid-2-phosphoric ester salt every 5 minutes by taking care not to cause gelation, and 30 minutes after the addition of L-ascorbic acid-2-phosphoric ester salt when the undissolved L-ascorbic acid-2-phosphoric ester salt is observed visually in the aqueous solution, determining the amount in weight percentage of L-ascorbic acid-2-phosphoric ester salt added based on water, and a method for feeding animals, using the preparation.

Preparation for administration to animals and feeding method thereof

A novel ascorbic acid derivative having both sufficiently improved stability and liposolubility, and facilitated cellular uptake. Also disclosed is a process for producing the derivative and a composition capable of effectively providing the action of vitamin C, for use in medical preparations, agricultural chemicals, animal drugs, foods, feeds or cosmetic preparations. The ascorbic acid derivative is a compound represented by the following formula (1) or a salt thereof: ##STR1## wherein R represents an acyl group having eleven or more carbon atoms and n is 0, 1 or 2.

Ascorbic acid derivative and vitamin C preparation containing the same

Disclosed herein are a highly purified tocopheryl phosphate and/or a salt thereof (tocopheryl phosphates) wherein a P,P'-bistocopheryl hypophosphate and/or a salt thereof (P,P'-bistocopheryl diphoshates) is contained in a proportion of not higher than 3% by weight; a process for producing a highly purified tocopheryl phosphate and/or a salt thereof, which comprises the steps of reacting a tocopherol with an oxyphosphorus trihalide followed by treating with an acid or basic aqueous solution to thereby form tocopheryl phosphates (i) in which P,P'-bistocopheryl diphoshates (ii) formed as by-products are contained, hydrolyzing the P,P'-bistocopheryl diphoshates (ii) under acid condition, and, optionally, rendering the hydrolyzate neutral or basic under basic condition; and a method of analyzing tocopheryl phosphates, comprising analyzing a sample containing components (i) and (ii) with the use of a high-performance liquid chromatograph column packed with a gel of a polymethacrylate having, bonded thereto, long-chain alkyl groups. None or only an extremely minute amount of P,P'-bistocopheryl diphoshates are contained in the highly purified tocopheryl phosphates, so that the highly purified tocopheryl phosphates exhibit antioxidant and blood circulation promoting effects, have excellent water solubility, are powdery so that the handling thereof is extremely easy, are free from cutaneous irritation and allergenecity and ensure dermal safety. Therefore, the highly purified tocopheryl phosphates are useful as cosmetic ingredients. The amounts of components (i) and (ii) can be simply measured with high accuracy by the above method.

Highly purified tocopheryl phosphate, process for producing the same,

A vitamin E source composition for administration to animals, which comprises a tocopheryl phosphate, a salt thereof or a composition containing a tocopheryl phosphate or a salt thereof. Also, disclosed is a method of supplying vitamin E to animals which comprises administering to animals the above vitamin E source composition. The tocopheryl phosphoric acid and a salt thereof can be formed into a composition and also can contain an antioxidant or the like.

Method of administering vitamin E to animals and compositions containing

High-  purity tocopherol phosphates, process for the preparation

An anti-stress agent for animals for reducing the growth inhibition or mortality of animals and a method of reducing stress using a feed composition having blended therein the anti-stress agent. The anti-stress agent for animals comprises one or more substances selected from L-ascorbic acid-2-phosphoric acid, a salt thereof and an L-ascorbic acid-2-glucoside, as an active ingredient, for inhibiting the increase of blood plasma lactate dehydrogenase (LDH), malate dehydrogenase (MDH) and aspartate aminotransferase (AspAT) and for inhibiting the increase of stress proteins in blood, which occur when animals are placed under stress. Also disclosed is a feed composition comprising the anti-stress agent, and a method of reducing the stress of animals by supplying the same as feed.

Anti-stress agent for animals and a method of reducing stress in animals

An L-ascorbic acid drug for intracerebral administration comprising one or more stable activity L-ascorbic acid compounds and one or more blood brainbarrier deobstruents. Also disclosed is a method for increasing intracerebral concentration of L-ascorbic acid in a human being comprising administering by injection an L-ascorbic acid drug comprising one or more stable activity L-ascorbic acid compounds. Additionally disclosed is a method for increasing intracerebral concentration of L-ascorbic acid in a human being comprising administering by injection an L-ascorbic acid drug comprising one or more stable activity L-ascorbic acid compounds and one or more blood brainbarrier deobstruents. Also disclosed is a method for treating diseases or disorders that result from intracerebral bloodstream inhibition or intracerebral bloodstream lowering comprising administering by injection to a person in need of such treatment, a dosage effective amount of an L-ascorbic acid drug comprising one or more stable activity L-ascorbic acid compounds. Additionally disclosed is a method for treating diseases or disorders that result from intracerebral bloodstream inhibition or intracerebral bloodstream lowering comprising administering by injection to a person in need of such treatment, a dosage effective amount of an L-ascorbic acid drug comprising one or more stable activity L-ascorbic acid compounds and one or more blood brainbarrier deobstruents.

Growing community of inventors

Tokyo, Japan

Eiji Ogata